Pfizer (NYSE:PFE) Trading 0.4% Higher – Still a Buy?

Shares of Pfizer Inc. (NYSE:PFE) rose 0.4% during trading on Wednesday . The stock traded as high as $26.50 and last traded at $26.42. Approximately 6,404,602 shares changed hands during mid-day trading, a decline of 82% from the average daily volume of 35,703,009 shares. The stock had previously closed at $26.31.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. UBS Group lowered their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. Bank of America reissued a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. Citigroup lowered their target price on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Finally, Truist Financial lowered their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Stock Down 0.6 %

The stock has a market cap of $147.49 billion, a price-to-earnings ratio of 18.46, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The firm’s 50-day moving average is $26.18 and its 200 day moving average is $27.07. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same period last year, the company posted $0.10 EPS. The business’s quarterly revenue was up 24.7% on a year-over-year basis. Sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.06% of the company’s stock.

Hedge Funds Weigh In On Pfizer

Institutional investors have recently added to or reduced their stakes in the company. Retirement Wealth Solutions LLC acquired a new position in Pfizer in the fourth quarter worth about $26,000. Rialto Wealth Management LLC acquired a new stake in shares of Pfizer during the 4th quarter worth approximately $26,000. Clarity Asset Management Inc. bought a new position in Pfizer during the 4th quarter worth $27,000. Gould Capital LLC boosted its stake in Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 493 shares during the period. Finally, Kohmann Bosshard Financial Services LLC acquired a new position in shares of Pfizer during the fourth quarter worth approximately $28,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.